Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/20072
Title: Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis
Authors: Almeida, Roque Pacheco de
D'Oliveira Júnior, Argemiro
Machado, Paulo Roberto Lima
Bacellar, Maria Olívia Amado Ramos
Ko, Albert Icksang
Jesus, Amélia Maria Ribeiro de
Mobashery, N
Santos, Jussamara Brito
Carvalho Filho, Edgar Marcelino
Affilliation: Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Abstract: The response to recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis was evaluated. Twenty patients with cutaneous leishmaniasis who had lesions for 60 days were enrolled in a double-blind placebo trial of GM-CSF with standard parenteral sodium stibogluconate (20 mg/kg-1/day-1) for 20 days. Ten patients were randomized to receive intralesionally injected GM-CSF (200 microgram) at enrollment and 1 week after, and 10 patients received saline as placebo. GM-CSF- and antimony-treated patients healed faster than patients who received antimony alone (49+/-32.8 vs. 110+/-61.6 days, P<.05). Seven of 10 patients were healed of their lesions before 40 days after therapy in the GM-CSF group, compared with only 1 of 10 patients in the placebo group (relative risk, 7; 95% confidence interval, 1.04-47.00). Thus, GM-CSF plus antimony significantly increased the chance of lesion healing in 40 days.
Keywords: Leishmaniasis, Cutaneous
Antimony Sodium Gluconate
Antiprotozoal Agents
Granulocyte-Macrophage Colony-Stimulating Factor
Child
Humans
keywords: Leishmaniose cutânea
Gluconato de antimônio e sódio
Agentes antiprotozoários
Fator Estimulador de Colônia de Granulócitos
Criança
Humanos
Issue Date: 1999
Publisher: Oxford University Press
Citation: ALMEIDA, R. P. et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. Journal of Infectious Diseases, v. 180, p. 1735–1737, 1999.
Description: Ko, Albert Icksang “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.
DOI: 10.1086/315082
ISSN: 0022-1899
Copyright: open access
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Almeida R Randomized, double-blind study of.... .pdf74.33 kBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.